Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease

NCT02231905 ·Status: COMPLETED ·Phase: PHASE4

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

NCT02177357 ·Status: COMPLETED ·Phase: PHASE3

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

NCT00274131 ·Status: COMPLETED ·Phase: PHASE3

Survey on PD Patients With Depressive Symptoms

NCT00614575 ·Status: COMPLETED

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

NCT02236728 ·Status: COMPLETED

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

NCT01097421 ·Status: COMPLETED

Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease

NCT00539214 ·Status: COMPLETED

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

NCT00297778 ·Status: COMPLETED ·Phase: PHASE4

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

NCT00148486 ·Status: COMPLETED ·Phase: PHASE2

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

NCT01096186 ·Status: COMPLETED ·Phase: PHASE3

Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

NCT00144209 ·Status: COMPLETED ·Phase: PHASE3

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

NCT01634360 ·Status: TERMINATED ·Phase: PHASE2

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

NCT00163085 ·Status: COMPLETED ·Phase: PHASE2

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

NCT02233023 ·Status: COMPLETED ·Phase: PHASE4

The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease

NCT01470859 ·Status: COMPLETED ·Phase: NA

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

NCT00144300 ·Status: COMPLETED ·Phase: PHASE4

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

NCT00335166 ·Status: COMPLETED ·Phase: PHASE3

Ambroxol in Disease Modification in Parkinson Disease

NCT02941822 ·Status: COMPLETED ·Phase: PHASE2

A Study to Examine APL-130277 in Patients With Parkinson's Disease

NCT02228590 ·Status: COMPLETED ·Phase: PHASE2

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

NCT00666653 ·Status: COMPLETED ·Phase: PHASE1

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

NCT02469090 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

NCT01130493 ·Status: COMPLETED ·Phase: PHASE3

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00660387 ·Status: COMPLETED ·Phase: PHASE3

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

NCT00880620 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2